“The start of phase 2 clinical trials for the Marburg vaccine is a major milestone for us and we appreciate the continued confidence of IN THE BAR in our work and our support in this next critical step,” says the CEO Sabin, Amy Finan. “Vaccines are still our best bet against death and disability from deadly viruses. I am hopeful that in the coming years we will be able to offer this life-saving vaccine to every person who needs it.”
More in-
Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans. So far no treatment has been approved for the hemorrhagic fever caused by filoviruses. Marburg and Ebola viruses are transmitted to humans by infected animals, especially fruit bats. Once a person is infected, the virus can spread to others through personal contact or contact with bodily fluids.